High risk, high reward – the future of CAR-T therapy in CLL
Pharmaceutical Technology
OCTOBER 5, 2022
Autologous CAR-T therapy does not easily lend itself to treating CLL, as it relies on extracting functional T-cells from the patient’s blood and genetically modifying them in vitro. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.
Let's personalize your content